Thailand’s Chulalongkorn University is seeking approval from the Thai Food and Drug Administration (TFDA) to begin the first two phases of human trials of its mRNA COVID-19 vaccine. According to…
Read More
Thailand’s Chulalongkorn University is seeking approval from the Thai Food and Drug Administration (TFDA) to begin the first two phases of human trials of its mRNA COVID-19 vaccine. According to…
Read More
The faculties of Dentistry and Tropical Medicine at Thailand’s Mahidol University claim to have jointly developed a mouthwash formula which is 99% effective at killing the COVID-19 virus in the…
Read More
The mRNA vaccine, currently being developed by the Vaccine Research Centre of the Faculty of Medicine of Chulalongkorn University, can stimulate the immune system to produce killer T-cells which can…
Read More
The first phase of human trials of a COVID-19 protein subunit vaccine, jointly developed by the Vaccine Research Centre of Chulalongkorn University and Baiya Phytopharm Company, will be launched in…
Read More
Thai virologists, at the National Centre for Genetic Engineering and Biotechnology (BIOTEC), have been developing two candidate nasal spray vaccines, or vaccine inhalers, which they hope will provide an option…
Read More
Thailand’s Chulalongkorn University’s Centre of Excellence in Vaccine Research and Development is recruiting 174 volunteers for human trials of its vaccine, known as ChulaCov19, scheduled to start at the end…
Read More
Thailand will begin the first stage of human trials in March of a new COVID-19 vaccine, which has been developed jointly by the Faculty of Tropical Medicine of Mahidol University…
Read More
Chulalongkorn University’s vaccine research centre will start human trials of its mRNA vaccine candidate, tentatively in April, after it received prototype vaccine from two factories in California. The centre’s director,…
Read More
The first anti-COVID-19 vaccines are expected to be available for use in humans next year, at an estimated cost of 620 baht per dose, said Dr. Siriroek Songsivilai, secretary-general of…
Read MorePage 1 of 1